tiprankstipranks
Advertisement
Advertisement
Balanced Risk-Reward on Summit Therapeutics as Ivonescimab Lung Cancer Data Show Weaker PFS but Encouraging Overall Survival, Supporting Hold Rating
PremiumRatingsBalanced Risk-Reward on Summit Therapeutics as Ivonescimab Lung Cancer Data Show Weaker PFS but Encouraging Overall Survival, Supporting Hold Rating
9d ago
Summit Therapeutics upgraded to Market Perform from Underperform at Leerink
Premium
The Fly
Summit Therapeutics upgraded to Market Perform from Underperform at Leerink
9d ago
Summit says Akeso receives marketing authorization in China for ivonescimab
Premium
The Fly
Summit says Akeso receives marketing authorization in China for ivonescimab
9d ago
Summit announces expansion of development program for ivonescimab
PremiumThe FlySummit announces expansion of development program for ivonescimab
21d ago
Summit Therapeutics: KOL Backing for Ivonescimab in NSCLC Reinforces Buy Rating and Unchanged $41 Price Target
Premium
Ratings
Summit Therapeutics: KOL Backing for Ivonescimab in NSCLC Reinforces Buy Rating and Unchanged $41 Price Target
28d ago
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations
Premium
Company Announcements
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations
1M ago
Summit Therapeutics price target lowered to $38 from $40 at Guggenheim
PremiumThe FlySummit Therapeutics price target lowered to $38 from $40 at Guggenheim
1M ago
Closing Bell Movers: Intel up 4% on Q2 earnings beat
Premium
The Fly
Closing Bell Movers: Intel up 4% on Q2 earnings beat
1M ago
Summit Therapeutics Establishes $380 Million ATM Equity Program
Premium
Company Announcements
Summit Therapeutics Establishes $380 Million ATM Equity Program
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100